INVENTIVA SA - ADR (IVA)
US46124U1079 - ADR
INVENTIVA SA - ADR
NASDAQ:IVA (10/17/2024, 8:43:46 PM)
After market: 2.2721 -0.15 (-6.11%)2.42
0 (0%)
Company Profile
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. The company is headquartered in Daix, Occitanie and currently employs 112 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Company Info
INVENTIVA SA - ADR
50 rue de Dijon, Daix
Daix OCCITANIE 21121
P: 33380447500
CEO: Frederic Cren
Employees: 122
Website: https://inventivapharma.com/
IVA News
a day ago - ChartmillUnusual volume stocks in Wednesday's sessionIn today's session, these stocks are experiencing unusual volume.
2 days ago - ChartmillThese stocks have an unusual volume in today's sessionLet's have a look at the stocks with an unusual volume in today's session.
4 days ago - Yahoo FinanceWhy Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday?Inventiva SA (NASDAQ:IVA) stock traded higher on Monday, with a strong session volume of 8.55 million compared to an average volume of 9.91k, according to data from Benzinga Pro. The company announced it has secured financing of immediately 94.1 million euros ($99.36 million) and up to 348 million euros ($379.55 million) to fund the completion of the Phase 3 NATiV3 MASH trial and preparation for the potential filing for marketing approval and commercialization of lanifibranor. The Transaction wa
7 months ago - The Motley FoolMadrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
8 months ago - Seeking AlphaInventiva stock drops after delay in Phase 3 NASH trialInventiva (IVA) stock plummeted as it announced a delay in its Phase 3 trial for NASH candidate lanifibranor due to an adverse event. Read more here.
IVA Twits
Here you can normally see the latest stock twits on IVA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
